Plasma hepcidin in early-stage breast cancer patients: No relationship with interleukin-6, erythropoietin and erythroferrone

Expert Review of Proteomics

Volumn 12, Issue 6, 2015, Pages 695-701

  Ciniselli, Chiara Maura ^a   De Bortoli, Maida ^a   Taverna, Elena ^a   Varinelli, Luca ^a   Pizzamiglio, Sara ^a   Veneroni, Silvia ^a   Bonini, Chiara ^a   Orlandi, Rosaria ^a   Verderio, Paolo ^a   Bongarzone, Italia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

benign breast disease; BMP6; breast cancer; early diagnosis; erytroferrone; erytropoiesis; erytropoietin; hepcidin; IL 6; inflammation; iron metabolism

Indexed keywords

ERYTHROFERRONE; ERYTHROPOIETIN; HEPCIDIN; INTERLEUKIN 6; UNCLASSIFIED DRUG; FAM132B PROTEIN, HUMAN; PEPTIDE HORMONE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; DISEASE ASSOCIATION; EARLY CANCER; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; PROTEIN BLOOD LEVEL; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; BLOOD; BREAST TUMOR; CASE CONTROL STUDY; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CASE-CONTROL STUDIES; ERYTHROPOIETIN; FEMALE; HEPCIDINS; HUMANS; INTERLEUKIN-6; MIDDLE AGED; PEPTIDE HORMONES;

EID: 84947490233     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.2015.1099436     Document Type: Article

References (33)

1. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012; 1823 (9): 1434-1443.
2. Camaschella C, Silvestri L. New and old players in the hepcidin pathway. Comment on Haematologica. 2008; 93 (10): 1473-1479.
3. Kautz L, Jung G, Valore EV, et al. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat.Genet. 2014; 46 (7): 678-684.
4. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004; 113: 1271-1276.
5. Ganz T, Olbina T, Girelli G, et al. Immunoassay for human hepcidin. Blood. 2008; 112: 4292-4297.
6. Maes K, Nemeth E, Roodman GD, et al. In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood. 2010; 116 (18): 3635-3644.
7. Tanno T, Rabel A, Alleyne M, et al. Hepcidin, anaemia, and prostate cancer. BJU Int. 2011; 107: 678-679.
8. Kamai T, Tomosugi N, Abe H, et al. Increased serum hepcidin-25 level and increased tumor expression of hepcidin mRNA are associated with metastasis of renal cell carcinoma. BMC Cancer. 2009; 9: 270.
9. Bohlius J, Weingart O, Trelle S, et al. Cancer-related anemia and recombinant human erythropoietin-an updated overview. Nat Clin Pract Oncol. 2006; 3: 152-164.
10. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004; 306: 2090-2093.
11. Orlandi R, De Bortoli M, Ciniselli CM, et al. Hepcidin and ferritin blood level as noninvasive tools for predicting breast cancer. Ann Oncol. 2014; 25 (2): 352-357.
12. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med. 2004; 116 (Suppl. 7A): 11S-26S.
13. Durigova A, Lamy PJ, Thezenas S, et al. Anemia and iron biomarkers in patients with early breast cancer. Diagnostic value of hepcidin and soluble transferrin receptor quantification. Clin Chem Lab Med. 2013; 51: 1833-1841.
14. Caro JJ, Salas M, Ward A, et al. Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review. Cancer. 2001; 91: 2214-2221.
15. Troutt JS, Rudling M, Persson L, et al. Circulating human hepcidin-25 concentrations display a diurnal rhythm, increase with prolonged fasting, and are reduced by growth hormone administration. Clin Chem. 2012; 58: 1225-1232.
16. Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, et al. Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood. 2011; 117: e218-25.
17. Thomas DW, Hinchliffe RF, Briggs C, et al. British Committee for Standards in Haematology. Guideline for the Laboratory Diagnosis of Functional iron Deficiency. Br J Haematol. 2013; 161: 639-648.
18. Enko D, Wagner H, Kriegshäuser G, et al. Hepcidin-25 vs. conventional clinical biomarkers in the diagnosis of functional iron deficiency iron deficiency. Br J Haematol. 2013; 161: 639-648.
19. D'Auria L, Bonifati C, Mussi A, et al. Cytokines in the sera of patients with pemphigus vulgaris: interleukin-6 and tumor necrosis factor-alfa levels are significantly increased as compared to healthy subjects and correlate with disease activity. Eur Cytokine Netw. 1997; 8: 383-387.
20. Hollander M, Wolfe DA. Nonparametric statistical methods. 2nd ed. New York: John Wiley & Sons; 1999.
21. Artusi R, Verderio P, Marubini E. Bravais-Pearson and Spearman correlation coefficients: meaning, test of hypothesis and confidence interval. Int J Biol Markers. 2002; 17: 148-151.
22. Shu T, Jing C, Lv Z, et al. Hepcidin in tumor-related iron deficiency anemia and tumor-related anemia of chronic disease: pathogenic mechanisms and diagnosis. Eur J Haematol. 2015; 94 (1): 67-73.
23. Ludwig H, Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large multinational, prospective survey defining prevalence, incidence and treatment of anaemia in cancer patients. Eur J Cancer. 2004; 40: 2293-2306.
24. Macciò A, Madeddu C, Gramignano G, et al. The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study. Haematologica. 2015; 100: 124-132.
25. Zhang GJ, Adachi I. Serum interleukin-6 levels correlate to tumour progression and prognosis in metastatic breast carcinoma. Anticancer Res. 1999; 19: 1427-1432.
26. Nemeth E, Valore EV, Territo M, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003; 101 (7): 2461-2463.
27. Hepcidin GT. a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003; 102: 783-788.
28. McCranor BJ, Kim MJ, Cruz NM, et al. Interleukin-6 directly impairs the erythroid development of human TF-1 erythroleukemic cells. Blood Cells Mol Dis. 2014; 52 (2-3): 126-133.
29. Knupfer H, Preiss R. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat. 2007; 102: 129-135.
30. Salgado R, Junius S, Benoy I, et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer. 2003; 103: 642-646.
31. Casanovas G, Mleczko-Sanecka K, Altamura S, et al. Bone morphogenetic protein (BMP)-responsive elements located in the proximal and distal hepcidin promoter are critical for its response to HJV/BMP/SMAD. J Mol Med. 2009; 87 (5): 471-480.
32. Alarmo EL, Kallioniemi A. Bone morphogenetic proteins in breast cancer: dual role in tumourigenesis? Endocr Relat Cancer. 2010; 17 (2): R123-39.
33. Van Houten EL, Laven JS, Louwers YV, et al. Bone morphogenetic proteins and the polycystic ovary syndrome. J Ovarian Res. 2013; 6 (1): 32.